Market Newsdesk

Initial AlloNK® (AB-101) clinical data demonstrated 71% ACR50 response in refractory rheumatoid arthritis (RA) patients with at least six months of follow-up in the company-sponsored Phase 2a basket trial, with no patients relapsing or requiring new immunomodulatory agents

AlloNK treatment regimen demonstrated a consistent pattern of deep B-cell depletion and tolerability results supportive of outpatient administration in community rheumatology settings

U.S. Food and Drug Administration (FDA) alignment on a single Phase 3 registrational randomized controlled trial evaluating AlloNK plus rituximab versus rituximab alone in approximately 150 refractory RA patients, with ACR50 at six months as the primary endpoint; trial initiation planned for H2 2026

Multiple oral and poster presentations at EULAR 2026, including a late-breaking oral presentation on AlloNK clinical efficacy in refractory RA, Sjögren disease (SjD) and systemic sclerosis (SSc)

SAN DIEGO, May 08, 2026 (GLOBE NEWSWIRE) — Artiva Biotherapeutics, Inc. (Nasdaq: ARTV) (Artiva), a clinical-stage biotechnology company whose mission is to develop effective, safe and accessible cell therapies for patients with debilitating autoimmune diseases, today announced financial results for the first quarter ended March 31, 2026, and highlighted recent progress.

“Artiva has reached an important inflection point, with positive initial clinical data across multiple autoimmune diseases and FDA alignment on a single Phase 3 registrational trial design in refractory RA,” said Fred Aslan, M.D., president and chief executive officer of Artiva Biotherapeutics. “The initial RA data demonstrated meaningful responses in highly refractory patients, alongside a tolerability profile supportive of outpatient administration in community rheumatology settings. Together, these data support AlloNK’s potential to become the first deep B-cell depleting therapy to advance into a Phase 3 trial in refractory RA, the autoimmune indication with the largest number of refractory patients.”

Dr. Aslan continued, “By combining deep B-cell depletion, meaningful clinical responses and an outpatient profile suited to community rheumatology practices, AlloNK has the potential to redefine the treatment paradigm for patients with refractory autoimmune disease.”

Recent Business Highlights

Reported positive initial clinical data from ongoing clinical trials evaluating AlloNK in combination with rituximab across multiple autoimmune diseases

• As of the April 3, 2026 data cutoff, the initial clinical dataset included 21 refractory RA patients with at least 12 weeks of follow-up, including 13 patients with at least six months of follow-up, from Artiva’s company-sponsored Phase 2a basket trial and an investigator-initiated basket trial evaluating AlloNK in B-cell driven autoimmune diseases. The broader autoimmune dataset also included 11 SjD patients and five SSc patients, including seven SjD patients and four SSc patients with at least six months of follow-up.
• In refractory RA, clinically meaningful improvements were observed across multiple measures of disease activity, including ACR responses, CDAI and DAS28-ESR. Five of seven patients (71%) with six months of follow-up in the company-sponsored Phase 2a basket trial achieved an ACR50 response. Nineteen of 21 RA patients demonstrated clinically meaningful reductions from baseline in both CDAI and DAS28-ESR.
• The AlloNK treatment regimen demonstrated tolerability results supportive of outpatient administration in community rheumatology settings, with no CRS, ICANS or treatment discontinuations related to AlloNK reported as of the data cutoff.
• Deep B-cell depletion was observed across evaluable patients, including complete B-cell depletion using a high-sensitivity assay in all 28 RA patients evaluated as of the data cutoff, supporting AlloNK’s proposed mechanism of action.
• Clinical responses in SjD and SSc were consistent with the RA data and support the potential of AlloNK across B-cell-driven autoimmune diseases.
• More than 70 autoimmune patients have been treated with AlloNK across more than 40 active clinical sites, mostly in community rheumatology settings, providing a strong foundation for planned registrational trial initiation.

Achieved FDA alignment on Phase 3 registrational trial design in refractory RA

• Artiva announced alignment with the FDA on a single Phase 3 registrational randomized controlled trial evaluating AlloNK plus rituximab versus rituximab alone in approximately 150 refractory RA patients, with ACR50 response at six months as the primary endpoint.

Upcoming Milestones

Present AlloNK clinical data at EULAR 2026

• Multiple abstracts accepted for presentation at EULAR 2026, expected to further characterize AlloNK’s mechanism of action, clinical activity and outpatient feasibility, including:
  • Late Breaking Oral Abstract Presentation – LB0003: AB-101, an Outpatient-Administered Allogeneic NK Cell Therapy Combined with Rituximab, Generates Robust Clinical Efficacy Responses Comparable with Autologous CAR T in 31 Patients with Rheumatologic Diseases

• • Oral Abstract Presentation – OP0129: AB-101, an Allogeneic NK Cell Therapy, Combined with Rituximab was Highly Effective in Severe Sjögren Disease: Experience in First Patient Treated
  • Poster View Presentation – POS1177: Robust and Durable Clinical Responses Observed Following Treatment with AB-101, an Allogeneic NK Cell Therapy, Combined with Rituximab in Patients with Severe Rheumatoid Arthritis and Inadequate Response to Multiple Prior Targeted Therapies
  • Poster Tour – POS0355: AB-101, an Allogeneic NK Cell Therapy, in Combination with Anti-CD20 Monoclonal Antibodies, Consistently Achieves Deep B-cell Depletion Comparable with CAR T Cell Therapies in Patients with Rheumatologic Diseases

Initiate Phase 3 registrational trial in refractory RA

• In the second half of 2026, Artiva plans to initiate a Phase 3 randomized controlled trial evaluating AlloNK plus rituximab versus rituximab alone in approximately 150 RA patients who have had an inadequate response to two or more biologic or targeted synthetic disease-modifying anti-rheumatic drugs (b/tsDMARDs) of distinct classes, with ACR50 response at six months as the primary efficacy endpoint.
  
  

First Quarter 2026 Financial Results

• Cash, Cash Equivalents and Investments
  
  .
  
   As of March 31, 2026, Artiva had cash, cash equivalents and investments of $86.8 million, which is expected to fund operations into Q2 2027.

• Research and Development Expenses.
   Research and development expenses were $19.3 million for the three months ended March 31, 2026, compared to $17.1 million for the three months ended March 31, 2025.

• General and Administrative Expenses.
   General and administrative expenses were $5.1 million for each of the three months ended March 31, 2026 and 2025.

• Other Income, net.
   Other income, net, was $0.9 million for the three months ended March 31, 2026, compared to other income, net, of $1.9 million for the three months ended March 31, 2025.

• Net Loss.
   Net loss totaled $23.5 million for the three months ended March 31, 2026, as compared to net loss of $20.3 million for the three months ended March 31, 2025, with non-cash stock-based compensation expense of $1.6 million and $2.1 million for the three months ended March 31, 2026 and 2025, respectively.

About Artiva Biotherapeutics

Artiva is a clinical-stage biotechnology company whose mission is to develop effective, safe and accessible cell therapies for patients with debilitating autoimmune diseases. Artiva’s lead program, AlloNK® (also known as AB-101), is an allogeneic, off-the-shelf, non-genetically modified, cryopreserved NK cell therapy candidate designed to enhance the antibody-dependent cellular cytotoxicity effect of monoclonal antibodies to drive B-cell depletion. AlloNK is currently being evaluated in three ongoing clinical trials for the treatment of B-cell driven autoimmune diseases, including a company-sponsored basket trial across autoimmune diseases that includes rheumatoid arthritis and Sjögren’s disease and an investigator-initiated basket trial in B-cell driven autoimmune diseases. Artiva plans to initiate a Phase 3 registrational trial evaluating AlloNK in refractory RA in 2026. Artiva was founded in 2019 as a spin out of GC Cell, formerly GC Lab Cell Corporation, a leading healthcare company in the Republic of Korea, pursuant to a strategic partnership granting Artiva exclusive worldwide rights (excluding Asia, Australia and New Zealand) to GC Cell’s NK cell manufacturing technology and programs.

Artiva is headquartered in San Diego, California. For more information, please visit www.artivabio.com.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Statements in this press release that are not statements of historical fact are forward-looking statements.  Such forward-looking statements include, without limitation, statements regarding: expectations of Artiva regarding the potential benefits, accessibility, effectiveness and safety of AlloNK®, including based on interim pooled data across clinical trials; Artiva’s registrational strategy, including trial design, plans to conduct a single registrational Phase 3 trial for AlloNK® and generate sufficient trial and pooled safety data to support a BLA submission, and Artiva’s expectations on timing and FDA alignment with such strategy; Artiva’s expectations on the timing to initiate and report data for the Phase 3 trial; Artiva’s expectations with respect to ACR50 responses in the Phase 3 trial for both AlloNK® and the control arm; estimates regarding the size of patient populations and response rates to existing therapies; the potential market opportunity for AlloNK®; Artiva’s future results of operations and financial position, including cash runway; and Artiva’s presentation plans.  These forward-looking statements are based on the beliefs of the management of Artiva as well as assumptions made by and information currently available to Artiva. Such statements reflect the current views of Artiva with respect to future events and are subject to known and unknown risks and uncertainties, including, without limitation, risks inherent in developing product candidates; Artiva’s ability to obtain adequate financing to fund its planned clinical trials and other expenses; risks that future clinical trial results may not be consistent with interim, initial, preliminary, or topline results or results from prior preclinical studies or clinical trials; the risk that Artiva’s registrational strategy is based in part on its views following its recent meeting with the FDA and later feedback from the FDA may be inconsistent with such meeting or its views from such meeting, including the risk that the official FDA minutes which Artiva expects to receive in the coming weeks may include interpretations, requests for additional data, or conclusions that differ from Artiva’s understanding of prior discussions; the risk that differences exist between trial designs, patient characteristics and other factors for the Artiva-sponsored Phase 2a basket trial and an investigator-initiated basket trial, and caution should be exercised in drawing any conclusions from such data across separate trials as such pooling and comparative data is inherently limited and such data may not be directly comparable; and risks related to the legal and regulatory framework for the industry. In light of these risks and uncertainties, the events or circumstances referred to in the forward-looking statements may not occur. These and other factors that may cause Artiva’s actual results to differ from current expectations are discussed in Artiva’s filings with the Securities and Exchange Commission (the “SEC”), including the section titled “Risk Factors” in Artiva’s Quarterly Report on Form 10-Q for the quarter ended March 31, 2026.  You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date this press release is given. Except as required by law, Artiva undertakes no obligation to publicly update any forward-looking statements, whether as a result of new information, future events or otherwise.

Artiva Biotherapeutics, Inc. Condensed Balance Sheets (Unaudited) (in thousands)
		March 31,			December 31,
		2026			2025
Assets
Cash, cash equivalents and investments		$	86,782		$	108,008
Property and equipment, net			6,216			6,618
Operating and financing lease right-of-use assets			10,080			10,737
Other assets			2,877			5,577
Total assets		$	105,955		$	130,940
Liabilities and stockholders’ equity
Accounts payable and accrued expenses		$	7,845		$	9,955
Operating and financing lease liabilities			10,263			10,942
Other liabilities			—			73
Total liabilities			18,108			20,970
Stockholders’ equity			87,847			109,970
Total liabilities and stockholders’ equity		$	105,955		$	130,940

Artiva Biotherapeutics, Inc. Condensed Statements of Operations and Comprehensive Loss (Unaudited) (in thousands, except share and per share data)
		Three Months Ended March 31,
			2026				2025
Operating expenses:
Research and development			19,312				17,052
General and administrative			5,118				5,119
Total operating expenses			24,430				22,171
Loss from operations			(24,430	)			(22,171	)
Other income, net:
Interest income			912				1,864
Other income (expense), net			2				(4	)
Total other income, net			914				1,860
Net loss		$	(23,516	)		$	(20,311	)
Net loss per share, basic and diluted		$	(0.95	)		$	(0.83	)
Weighted-average common shares outstanding, basic and diluted			24,678,420				24,341,978
Comprehensive loss:
Net loss		$	(23,516	)		$	(20,311	)
Other comprehensive (loss) income, net			(121	)			129
Comprehensive loss		$	(23,637	)		$	(20,182	)

Contacts

Investors

Noopur Batsha Liffick, MPH
NBL LifeSci Advisory LLC
[email protected]

Media
Jessica Yingling, Ph.D.
Little Dog Communications Inc.
[email protected]

Source: Artiva Biotherapeutics, Inc.

Initial clinical data demonstrated 71% ACR50 response in refractory rheumatoid arthritis (RA) patients with at least six months of follow-up in the company-sponsored Phase 2a basket trial, with no patients relapsing or requiring new immunomodulatory agents

AlloNK treatment regimen demonstrated tolerability results supportive of outpatient administration in community rheumatology settings, with no CRS, ICANS, or treatment discontinuations observed in autoimmune patients treated with AlloNK

More than 70 autoimmune patients treated with AlloNK across more than 40 active clinical sites, mostly in community settings, providing a strong foundation for planned registrational trial initiation in H2 2026

U.S. Food and Drug Administration (FDA) alignment on a single registrational randomized controlled trial evaluating AlloNK plus rituximab versus rituximab alone in approximately 150 refractory RA patients, with ACR50 at six months as the primary endpoint

Multiple oral and poster presentations at EULAR 2026, including a late-breaking oral presentation on AlloNK clinical efficacy in refractory RA, Sjögren disease (SjD) and systemic sclerosis (SSc)

SAN DIEGO, May 08, 2026 (GLOBE NEWSWIRE) — Artiva Biotherapeutics, Inc. (Nasdaq: ARTV) (Artiva), a clinical-stage biotechnology company whose mission is to develop effective, safe and accessible cell therapies for patients with debilitating autoimmune diseases, today announced positive initial clinical data from ongoing clinical trials evaluating AlloNK^® (also known as AB-101) in combination with rituximab. As of the April 3, 2026 data cutoff, the initial clinical dataset includes 21 refractory RA patients with at least 12 weeks of follow-up, including 13 patients with six months of follow-up, from Artiva’s company-sponsored Phase 2a basket trial and an investigator-initiated basket trial evaluating AlloNK in B-cell driven autoimmune diseases. The broader autoimmune dataset also includes 11 SjD patients and five SSc patients, including seven SjD patients and four SSc patients with at least six months of follow-up.

Artiva also announced alignment with the FDA on a single registrational randomized controlled trial design for AlloNK in refractory RA expected to enroll approximately 150 RA patients who have had an inadequate response to two or more biologic or targeted synthetic disease modifying anti-rheumatic drugs (b/tsDMARDs) of distinct classes. Patients are expected to be randomized 2:1 to receive AlloNK plus rituximab or rituximab alone, with ACR50 response at six months as the primary efficacy endpoint.

“A new chapter begins for Artiva as we advance the first deep B-cell depleting therapy into a registrational trial in RA and share clinical data demonstrating AlloNK’s potential to drive auto-CAR-T-like activity across indications through an off-the-shelf, more scalable and cost-effective therapeutic approach that could address refractory patients in the community setting,” said Fred Aslan, M.D., president and chief executive officer of Artiva Biotherapeutics. “I am very proud of the Artiva team. In less than four years since the seminal deep B-cell depletion work was published by Schett et al., we rapidly initiated and supported trials in autoimmune diseases, activated more than 40 sites globally, treated more than 70 autoimmune patients and built a robust clinical trial network, mostly in the community setting, to support our efforts to conduct an efficient randomized controlled trial in RA, one of the largest refractory autoimmune patient populations.”

“After reviewing AlloNK’s initial clinical data in refractory RA, I am encouraged by the magnitude and consistency of improvements across multiple measures of disease activity, including swollen and tender joint counts, CDAI, DAS28 and ACR responses,” said Stanley Cohen, M.D., adjunct professor of internal medicine at University of Texas Southwestern Medical School and program director of rheumatology at THR Presbyterian Dallas. “Patients who have had an inadequate response to multiple distinct b/tsDMARDs remain difficult to treat, and there is a significant need for new therapeutic approaches that can deliver meaningful clinical benefit. I am pleased to be advising Artiva on their planned Phase 3 registrational trial of AlloNK in refractory RA.”

“Since the inception of Artiva’s clinical trials in autoimmune diseases, I have treated more than 20 patients with AlloNK in my community practice and have observed meaningful improvements in many refractory patients across indications,” said Guillermo J. Valenzuela, M.D., F.A.C.R., medical director of Integral Rheumatology & Immunology Specialists (IRIS). “Importantly, these clinical responses have been observed alongside a favorable tolerability profile that supports administration and management in the community setting. I am enthusiastic to see AlloNK advance into a Phase 3 trial for refractory RA.”

As of April 30, 2026, more than 70 autoimmune patients had initiated treatment with AlloNK across ongoing clinical trials, with more than 40 clinical sites activated globally. All patients have been treated in the outpatient setting, with the majority treated in community rheumatology clinics, providing a strong foundation to support Artiva’s planned Phase 3 registrational trial in refractory RA.

Key Data Highlights

Initial clinical activity observed in refractory RA patients

• As of the April 3, 2026 data cutoff, pooled data included 21 refractory RA patients with at least 12 weeks of follow-up, including 13 patients with six months of follow-up, from Artiva’s company-sponsored Phase 2a basket trial and an investigator-initiated basket trial.
• Patients had longstanding and highly active disease, with mean disease duration of 14.8 years. All patients had high disease activity at baseline and 81% had failed two or more prior b/tsDMARD classes.
• Five of seven patients (71%) with six months of follow-up in the company-sponsored Phase 2a basket trial achieved an ACR50 response. In the investigator-initiated basket trial, five of six patients (83%) with six months of follow-up demonstrated greater than 50% improvement on at least four of five measured components; HAQ-DI and Pain scores were not collected in the IIT, and therefore ACR50 could not be adequately assessed. Patients with only 12 weeks of follow-up demonstrated early improvements across disease activity measures consistent with those observed in patients with six or more months of follow-up. As of the data cutoff, no patients started a new b/tsDMARD following treatment with AlloNK plus rituximab.
• Nineteen of 21 patients demonstrated clinically meaningful reductions from baseline in both CDAI (defined as reductions of at least 12 points) and DAS28-ESR (defined as reductions of at least 1.2 points). Clinically meaningful reductions in CDAI and DAS28-ESR were observed by three months and deepened at six months, with mean reductions from baseline at six months of 37 points in CDAI and 2.8 points in DAS28-ESR.

Tolerability profile of AlloNK plus rituximab continues to support outpatient administration in community rheumatology settings

• All patients have been treated in the outpatient setting, with the majority treated in community rheumatology clinics.
• No cytokine release syndrome (CRS) or immune effector cell-associated neurotoxicity syndrome (ICANS) was reported.
• No treatment discontinuations due to adverse events and no serious adverse events related to AlloNK were reported.
• The most common treatment-emergent adverse events were consistent with those associated with rituximab or cyclophosphamide/fludarabine conditioning. The Grade 3 or higher infection rate was 2% (n=1), which is comparable to serious infection rates reported for approved RA therapies, including rituximab and other biologic or targeted therapies.
• During the initial 28-day post-treatment period, no patients were hospitalized for infection. Two of 55 autoimmune patients treated with AlloNK plus rituximab were hospitalized for treatment-emergent adverse events during this period: one admission for dehydration in a SjD patient with diarrhea and one admission for diabetic ketoacidosis in a RA patient with insulin-dependent Type 2 diabetes. Neither hospitalization was deemed related to AlloNK.

Deep B-cell depletion and B-cell reconstitution profile support proposed mechanism of action

• Uniform and consistent B-cell depletion in peripheral blood was observed by Day 13 in all 51 patients treated with cyclophosphamide/fludarabine, AlloNK and rituximab who had available samples as of the April 3, 2026 data cutoff.
• Complete B-cell depletion was observed using a high-sensitivity assay in all 28 RA patients evaluated as of the data cutoff.
• B-cell reconstitution in all patients treated with AlloNK plus rituximab demonstrated a predominance of naïve/transitional B cells, consistent with the hypothesized B-cell “reset” mechanism.

Initial clinical responses in Sjögren disease and systemic sclerosis support broader potential across B-cell-driven autoimmune diseases

• As of the April 3, 2026 data cutoff, initial clinical data included 11 patients with moderate-to-severe SjD and five patients with moderate-to-severe SSc. Clinical responses observed in these patient populations were consistent with the RA data and support the potential of AlloNK across B-cell driven autoimmune diseases.
• In SjD, patients demonstrated mean improvements at six months (n=7) of 8.6 points in ClinESSDAI, 6.6 points in ESSDAI and 3.0 points in ESSPRI, with a mean increase of 0.76 mL/min in stimulated salivary flow. All patients were off steroids as of the April 3, 2026 data cutoff.
• In SSc, patients demonstrated a mean improvement in mRSS of 9.5 points at six months (n=4), with 100% achieving rCRISS25 and 50% achieving rCRISS50 responses among patients with six months of follow-up. No patients were on steroids as of the April 3, 2026 data cutoff.

FDA Alignment and Registrational Strategy in Refractory RA

Following a recent FDA interaction, Artiva plans to initiate a Phase 3 randomized controlled trial evaluating AlloNK in approximately 150 RA patients who have had an inadequate response to two or more b/tsDMARDs of distinct classes. Artiva has alignment with the FDA on its plans to conduct a single registrational trial. Patients are expected to be randomized 2:1 to receive AlloNK plus rituximab or rituximab alone, with ACR50 response at six months as the primary efficacy endpoint. Rituximab was selected as the active comparator because it is a component of the proposed AlloNK treatment regimen, is approved for the treatment of RA and has demonstrated ACR50 responses at six months in line with other approved RA therapies. Patients randomized to the rituximab-alone control arm who do not respond are expected to have the opportunity to cross over to the AlloNK plus rituximab arm at six months.

The proposed AlloNK dosing regimen is expected to include two doses of 4 billion AlloNK cells administered on Days 6 and 20 together with rituximab, following conditioning with low-dose cyclophosphamide and fludarabine on Days 1, 2 and 3.

Assuming a favorable risk-benefit profile, Artiva believes its ongoing and planned autoimmune clinical trials, including the planned Phase 3 registrational trial in refractory RA, will generate a safety database of more than 250 patients treated with AlloNK plus rituximab, consisting primarily of RA patients and including patients with other autoimmune diseases, to support a potential biologics license application (BLA) submission for RA. Based on FDA feedback, Artiva believes pooled safety data across multiple autoimmune indications may supplement RA-specific safety data.

Subject to final protocol and regulatory considerations, the trial is expected to be conducted globally across more than 80 sites, including approximately 40 sites already active in Artiva’s ongoing autoimmune clinical program. Artiva expects to initiate the registrational trial in the second half of 2026 and report primary efficacy data in the second half of 2028, with a potential BLA submission in 2029.

Significant opportunity and unmet need in refractory RA

RA remains a large and underserved autoimmune disease, particularly among patients who have had an inadequate response to two or more b/tsDMARD classes, also known as difficult-to-treat RA under EULAR guidelines. Artiva estimates that between 150,000 to 200,000 patients in the U.S. have failed two or more b/tsDMARDs, representing approximately 25% of the U.S. b/tsDMARD-treated RA population. Real-world registry analyses and published data suggest that patients in this setting only have an 11% to 19% likelihood of achieving an ACR50 response with currently available therapies.

Artiva’s objective is to develop AlloNK as a deep B-cell depleting therapy in combination with rituximab with the potential to deliver ACR50 responses in at least 50% of refractory RA patients at six months, provide durable clinical benefit and offer an outpatient treatment profile that can be administered and managed in community rheumatology settings. Artiva expects patients in the rituximab-alone control arm to achieve ACR50 responses of approximately 20% to 25% at six months.

Multiple abstracts accepted for presentation at

EULAR 2026

• Late Breaking Oral Abstract Presentation – LB0003: AB-101, an Outpatient-Administered Allogeneic NK Cell Therapy Combined with Rituximab, Generates Robust Clinical Efficacy Responses Comparable with Autologous CAR T in 31 Patients with Rheumatologic Diseases
• Oral Abstract Presentation – OP0129: AB-101, an Allogeneic NK Cell Therapy, Combined with Rituximab was Highly Effective in Severe Sjögren Disease: Experience in First Patient Treated
• Poster View Presentation – POS1177: Robust and Durable Clinical Responses Observed Following Treatment with AB-101, an Allogeneic NK Cell Therapy, Combined with Rituximab in Patients with Severe Rheumatoid Arthritis and Inadequate Response to Multiple Prior Targeted Therapies
• Poster Tour – POS0355: AB-101, an Allogeneic NK Cell Therapy, in Combination with Anti-CD20 Monoclonal Antibodies, Consistently Achieves Deep B-cell Depletion Comparable with CAR T Cell Therapies in Patients with Rheumatologic Diseases

About AlloNK^®

AlloNK^® (also known as AB-101) is an allogeneic, off-the-shelf, non-genetically modified, cryopreserved natural killer (NK) cell therapy candidate designed to enhance the antibody-dependent cellular cytotoxicity effect of monoclonal antibodies to drive B-cell depletion. In rheumatoid arthritis (RA) and other autoimmune diseases, AlloNK is being evaluated in combination with anti-CD20 monoclonal antibodies following a standard conditioning regimen of low-dose cyclophosphamide and fludarabine. AlloNK is currently being evaluated across multiple ongoing clinical trials in B-cell driven autoimmune diseases, including refractory RA, Sjögren disease, systemic sclerosis and idiopathic inflammatory myopathies (myositis).

About Artiva Biotherapeutics

Artiva is a clinical-stage biotechnology company whose mission is to develop effective, safe and accessible cell therapies for patients with debilitating autoimmune diseases. Artiva’s lead program, AlloNK^® (also known as AB-101), is an allogeneic, off-the-shelf, non-genetically modified, cryopreserved NK cell therapy candidate designed to enhance the antibody-dependent cellular cytotoxicity effect of monoclonal antibodies to drive B-cell depletion. AlloNK is currently being evaluated in three ongoing clinical trials for the treatment of B-cell driven autoimmune diseases, including a company-sponsored basket trial across autoimmune diseases that includes rheumatoid arthritis and Sjögren disease and an investigator-initiated basket trial in B-cell driven autoimmune diseases. Artiva plans to initiate a Phase 3 registrational trial evaluating AlloNK in refractory RA in 2026. Artiva was founded in 2019 as a spin out of GC Cell, formerly GC Lab Cell Corporation, a leading healthcare company in the Republic of Korea, pursuant to a strategic partnership granting Artiva exclusive worldwide rights (excluding Asia, Australia and New Zealand) to GC Cell’s NK cell manufacturing technology and programs.

Artiva is headquartered in San Diego, California. For more information, please visit www.artivabio.com.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Statements in this press release that are not statements of historical fact are forward-looking statements. Such forward-looking statements include, without limitation, statements regarding: expectations of Artiva regarding the potential benefits, accessibility, effectiveness and safety of AlloNK, including based on interim pooled data across clinical trials; Artiva’s registrational strategy, including trial design, plans to conduct a single registrational Phase 3 trial for AlloNK and generate sufficient trial and pooled safety data to support a BLA submission, and Artiva’s expectations on timing and FDA alignment with such strategy; Artiva’s expectations on the timing to initiate and report data for the Phase 3 trial; Artiva’s expectations with respect to ACR50 responses in the Phase 3 trial for both AlloNK and the control arm; estimates regarding the size of patient populations and response rates to existing therapies; and the potential market opportunity for AlloNK. These forward-looking statements are based on the beliefs of the management of Artiva as well as assumptions made by and information currently available Artiva. Such statements reflect the current views of Artiva with respect to future events and are subject to known and unknown risks and uncertainties, including, without limitation, risks inherent in developing product candidates; Artiva’s ability to obtain adequate financing to fund its planned clinical trials and other expenses; risks that future clinical trial results may not be consistent with interim, initial, preliminary, or topline results or results from prior preclinical studies or clinical trials; the risk that Artiva’s registrational strategy is based in part on its views following its recent meeting with the FDA and later feedback from the FDA may be inconsistent with such meeting or its views from such meeting, including the risk that the official FDA minutes which Artiva expects to receive in the coming weeks may include interpretations, requests for additional data, or conclusions that differ from Artiva’s understanding of prior discussions; the risk that differences exist between trial designs, patient characteristics and other factors for the Artiva-sponsored Phase 2a basket trial and an investigator-initiated basket trial, and caution should be exercised in drawing any conclusions from such data across separate trials as such pooling and comparative data is inherently limited and such data may not be directly comparable; and risks related to the legal and regulatory framework for the industry. In light of these risks and uncertainties, the events or circumstances referred to in the forward-looking statements may not occur. These and other factors that may cause Artiva’s actual results to differ from current expectations are described in further detail under the section titled “Risk Factors” contained in Artiva’s filings with the Securities and Exchange Commission (the “SEC”), including Artiva’s Annual Report on Form 10-K for the year ended December 31, 2025, and its subsequent Quarterly Reports on Form 10-Q, each as filed or to be filed with the SEC. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date this press release is given. Except as required by law, Artiva undertakes no obligation to publicly update any forward-looking statements, whether as a result of new information, future events or otherwise.

Contacts

Investors

Noopur Batsha Liffick, MPH
NBL LifeSci Advisory LLC
[email protected]

Media

Jessica Yingling, Ph.D.
Little Dog Communications Inc.
[email protected]

HAMILTON, Bermuda, May 08, 2026 (GLOBE NEWSWIRE) — Essent Group Ltd. (NYSE: ESNT) today reported net income for the quarter ended March 31, 2026 of $171.8 million or $1.82 per diluted share, compared to $175.4 million or $1.69 per diluted share for the quarter ended March 31, 2025.

Essent also announced today that its Board of Directors has declared a quarterly cash dividend of $0.35 per common share. The dividend is payable on June 10, 2026 to shareholders of record on June 1, 2026.

“We are pleased with our first quarter 2026 financial results, which continued to benefit from favorable credit trends and the impact of interest rates on both persistency and investment income,” said Mark A. Casale, Chairman and Chief Executive Officer. “The strong cash flow generation from our core mortgage insurance business and the strength of our buy, manage and distribute operating model have enabled us to take a balanced approach to capital management.”

Financial Highlights:

• Mortgage new insurance written for the first quarter of 2026 was $11.1 billion, compared to $11.8 billion in the fourth quarter of 2025 and $9.9 billion in the first quarter of 2025.
• Mortgage insurance in force as of March 31, 2026 was $247.9 billion, compared to $248.4 billion as of December 31, 2025 and $244.7 billion as of March 31, 2025.
• Net investment income for the first quarter of 2026 was $59.3 million, compared to $58.2 million in the first quarter of 2025.
• During the first quarter of 2026, Essent Guaranty entered into an excess of loss reinsurance transaction with a panel of highly rated third-party reinsurers providing forward protection, effective July 1, 2027, for business written in calendar year 2027.
• Year-to-date through April 30, 2026, Essent repurchased approximately 3.5 million common shares for over $214 million.

Conference Call:

Essent management will hold a conference call at 10:00 AM Eastern time today to discuss its results. The conference call will be broadcast live over the Internet at http://ir.essentgroup.com/events-and-presentations/events/default.aspx. The call may also be accessed by dialing 888-330-2384 inside the U.S., or 240-789-2701 for international callers, using passcode 9824537 or by referencing Essent.

A replay of the webcast will be available on the Essent website approximately two hours after the live broadcast ends for a period of one year. A replay of the conference call will be available approximately two hours after the call ends for a period of two weeks, using the following dial-in numbers and passcode: 800-770-2030 inside the U.S., or 647-362-9199 for international callers, passcode 9824537.

In addition to the information provided in the Company’s earnings news release, other statistical and financial information, which may be referred to during the conference call, will be available on Essent’s website at http://ir.essentgroup.com/financials/quarterly-results/default.aspx.

Forward-Looking Statements:

This press release may include “forward-looking statements” which are subject to known and unknown risks and uncertainties, many of which may be beyond our control. Forward-looking statements generally can be identified by the use of forward-looking terminology such as “may,” “will,” “should,” “expect,” “plan,” “anticipate,” “believe,” “estimate,” “predict,” or “potential” or the negative thereof or variations thereon or similar terminology. Actual events, results and outcomes may differ materially from our expectations due to a variety of known and unknown risks, uncertainties and other factors. Although it is not possible to identify all of these risks and factors, they include, among others, the following: changes in or to Fannie Mae and Freddie Mac (the “GSEs”), whether through Federal legislation, restructurings or a shift in business practices; failure to continue to meet the mortgage insurer eligibility requirements of the GSEs; competition for customers or the loss of a significant customer; lenders or investors seeking alternatives to private mortgage insurance; an increase in the number of loans insured through Federal government mortgage insurance programs; decline in the volume of low down payment mortgage originations; uncertainty of loss reserve estimates; decrease in the length of time our insurance policies are in force; deteriorating economic conditions; and other risks and factors described in Part I, Item 1A “Risk Factors” of our Annual Report on Form 10-K for the year ended December 31, 2025 filed with the Securities and Exchange Commission on February 18, 2026, as subsequently updated through other reports we file with the Securities and Exchange Commission. Any forward-looking information presented herein is made only as of the date of this press release, and we do not undertake any obligation to update or revise any forward-looking information to reflect changes in assumptions, the occurrence of unanticipated events, or otherwise.

About the Company:

Essent Group Ltd. (NYSE: ESNT) is a Bermuda-based holding company (collectively with its subsidiaries, “Essent”) offering private mortgage insurance, reinsurance, and title insurance and settlement services to serve the housing finance industry. Additional information regarding Essent may be found at www.essentgroup.com.

Source: Essent Group Ltd.

Media Contact

610.230.0556
[email protected] 

Investor Relations Contact

Philip Stefano
Vice President, Investor Relations
855-809-ESNT
[email protected] 

Essent Group Ltd. and Subsidiaries
Financial Results and Supplemental Information (Unaudited)
Quarter Ended March 31, 2026
Exhibit A		Condensed Consolidated Statements of Comprehensive Income (Unaudited)
Exhibit B		Condensed Consolidated Balance Sheets (Unaudited)
Exhibit C		Consolidated Historical Quarterly Data (Unaudited)
Exhibit D		Year to Date Segment Results (Unaudited)
Exhibit E		Historical Quarterly Segment Information (Unaudited)
Exhibit F		Mortgage Insurance – Historical Quarterly Data
Exhibit G		Mortgage Insurance – New Insurance Written
Exhibit H		Mortgage Insurance – Insurance in Force and Risk in Force
Exhibit I		Mortgage Insurance – Vintage Data
Exhibit J		Mortgage Insurance – Outward Reinsurance Vintage Data
Exhibit K		Mortgage Insurance – Geographic Data
Exhibit L		Mortgage Insurance – Rollforward of Defaults and Reserve for Losses and LAE
Exhibit M		Mortgage Insurance – Detail of Reserves by Default Delinquency
Exhibit N		U.S. Mortgage Insurance Company Capital
Exhibit O		Reinsurance
Exhibit P		Cash & Investments

	Exhibit A
Essent Group Ltd. and Subsidiaries
Condensed Consolidated Statements of Comprehensive Income (Unaudited)
	Three Months Ended March 31,
(In thousands, except per share amounts)		2026				2025
Revenues:
Gross premiums written	$	431,232			$	272,394
Ceded premiums		(36,563	)			(34,123	)
Net premiums written		394,669				238,271
(Increase) decrease in unearned premiums		(134,576	)			7,577
Net premiums earned		260,093				245,848
Net investment income		59,255				58,210
Realized investment gains (losses), net		(147	)			(181	)
Income from other invested assets		10,179				7,408
Other income		6,692				6,273
Total revenues		336,072				317,558
Losses and expenses:
Provision for losses and LAE		48,216				31,287
Other underwriting and operating expenses		72,983				71,124
Interest expense		8,148				8,148
Total losses and expenses		129,347				110,559
Income before income taxes		206,725				206,999
Income tax expense		34,926				31,566
Net income	$	171,799			$	175,433
Earnings per share:
Basic	$	1.83			$	1.71
Diluted		1.82				1.69
Weighted average shares outstanding:
Basic		93,818				102,881
Diluted		94,572				103,946
Net income	$	171,799			$	175,433
Other comprehensive income:
Unrealized appreciation (depreciation) of investments		(35,951	)			71,738
Comprehensive income	$	135,848			$	247,171

					Exhibit B
Essent Group Ltd. and Subsidiaries
Condensed Consolidated Balance Sheets (Unaudited)
	March 31,				December 31,
(In thousands, except per share amounts)		2026				2025
Assets
Investments
Fixed maturities available for sale, at fair value	$	5,425,210			$	5,455,593
Short-term investments available for sale, at fair value		623,034				648,492
Total investments available for sale		6,048,244				6,104,085
Other invested assets		394,290				382,513
Total investments		6,442,534				6,486,598
Cash		128,262				123,049
Accrued investment income		44,875				47,371
Accounts receivable		144,121				51,267
Deferred policy acquisition costs		56,901				9,547
Property, equipment and software, net		48,297				49,189
Prepaid federal income tax		513,425				513,425
Goodwill and acquired intangible assets, net		77,802				78,153
Other assets		113,551				82,404
Total assets	$	7,569,768			$	7,441,003
Liabilities and Stockholders’ Equity
Liabilities
Reserve for losses and LAE	$	485,666			$	446,822
Unearned premium reserve		226,306				91,730
Net deferred tax liability		452,552				465,351
Senior notes due 2029, net		495,637				495,301
Other accrued liabilities		213,105				185,072
Total liabilities		1,873,266				1,684,276
Commitments and contingencies
Stockholders’ Equity
Common shares, $0.015 par value:
Authorized – 233,333; issued and outstanding – 93,073 shares in 2026 and 95,456 shares in 2025		1,396				1,432
Additional paid-in capital		486,672				649,895
Accumulated other comprehensive loss		(187,936	)			(151,985	)
Retained earnings		5,396,370				5,257,385
Total stockholders’ equity		5,696,502				5,756,727
Total liabilities and stockholders’ equity	$	7,569,768			$	7,441,003
Return on average equity (1)		12.0	%			12.1	%
(1) The 2026 return on average equity is calculated by dividing annualized year-to-date 2026 net income by average equity. The 2025 return on average equity is calculated by dividing full year 2025 net income by average equity.

														Exhibit C
Essent Group Ltd. and Subsidiaries
Supplemental Information
Consolidated Historical Quarterly Data (Unaudited)
		2026					2025
		March 31				December 31				September 30				June 30				March 31
(In thousands, except per share amounts)
Revenues:
Net premiums earned		$	260,093			$	242,729			$	246,332			$	248,809			$	245,848
Net investment income			59,255				59,223				59,795				59,289				58,210
Realized investment gains (losses), net			(147	)			(188	)			(425	)			(129	)			(181	)
Income from other invested assets			10,179				3,942				1,770				4,466				7,408
Other income (1)			6,692				6,698				4,358				6,708				6,273
Total revenues			336,072				312,404				311,830				319,143				317,558
Losses and expenses:
Provision for losses and LAE			48,216				56,073				44,922				17,055				31,287
Other underwriting and operating expenses			72,983				63,653				59,498				62,765				71,124
Interest expense			8,148				8,149				8,251				8,148				8,148
Total losses and expenses			129,347				127,875				112,671				87,968				110,559
Income before income taxes			206,725				184,529				199,159				231,175				206,999
Income tax expense (2)			34,926				29,547				34,944				35,836				31,566
Net income		$	171,799			$	154,982			$	164,215			$	195,339			$	175,433
Earnings per share:
Basic		$	1.83			$	1.62			$	1.69			$	1.95			$	1.71
Diluted			1.82				1.60				1.67				1.93				1.69
Weighted average shares outstanding:
Basic			93,818				95,772				97,400				100,037				102,881
Diluted			94,572				96,664				98,519				101,059				103,946
Book value per share		$	61.20			$	60.31			$	58.86			$	56.98			$	55.22
Return on average equity (annualized)			12.0	%			10.8	%			11.5	%			13.8	%			12.5	%
Senior debt & credit facility:
Borrowings outstanding		$	500,000			$	500,000			$	500,000			$	500,000			$	500,000
Undrawn committed capacity		$	500,000			$	500,000			$	500,000			$	500,000			$	500,000
Weighted average interest rate (end of period)			6.25	%			6.25	%			6.25	%			6.25	%			6.25	%
Debt-to-capital			8.07	%			7.99	%			8.01	%			8.10	%			8.12	%
Cash and investments available for sale at the holding companies		$	1,144,112			$	1,268,579			$	1,038,747			$	995,032			$	1,016,368
(1) Other income includes net favorable (unfavorable) changes in the fair value of embedded derivatives associated with certain of our third-party reinsurance agreements, which for the quarters ended March 31, 2026, December 31, 2025, September 30, 2025, June 30, 2025, and March 31, 2025, were $37, ($526), ($858), ($29) and ($150), respectively.
(2) Income tax expense for the quarters ended March 31, 2026, December 31, 2025, September 30, 2025, June 30, 2025, and March 31, 2025 includes $2,407, $366, $493, $1,112, and $1,561, respectively, of discrete tax expense associated with realized and unrealized gains. Income tax expense for the quarters ended December 31, 2025 and September 30, 2025 also include ($396) and ($828), respectively, of discrete tax benefits associated with prior year tax returns. Income tax expense for the quarters ended March 31, 2026 and March 31, 2025 also include ($1,067) and ($742), respectively, of excess tax benefits associated with the vesting of common shares and common share units.

																														Exhibit D
Essent Group Ltd. and Subsidiaries
Supplemental Information
Year to Date Segment Results (Unaudited)
The following tables set forth comparative annual financial information for our two reportable business segments, Mortgage Insurance and Reinsurance, our Corporate & Other category and our consolidated results for the three months ended March 31, 2026 and 2025 (unaudited). Our Corporate & Other category is used to reconcile our reportable business segments to consolidated results and includes business activities associated with our title insurance operations, income and losses from holding company treasury operations, and general corporate operating expenses not attributable to our operating segments.
		Three Months Ended March 31, 2026																Three Months Ended March 31, 2025
(In thousands)		Mortgage Insurance				Reinsurance				Corporate & Other				Consolidated				Mortgage Insurance				Reinsurance				Corporate & Other				Consolidated
Revenues:
Net premiums earned		$	215,663			$	29,310			$	15,120			$	260,093			$	218,124			$	15,734			$	11,990			$	245,848
Net investment income			42,357				4,670				12,228				59,255				42,790				4,840				10,580				58,210
Realized investment gains (losses), net			(188	)			—				41				(147	)			(101	)			—				(80	)			(181	)
Income from other invested assets			5,762				—				4,417				10,179				3,209				—				4,199				7,408
Other income			1,743				1,971				2,978				6,692				1,548				2,953				1,772				6,273
Total revenues			265,337				35,951				34,784				336,072				265,570				23,527				28,461				317,558
Losses and expenses:
Provision for losses and LAE			37,620				9,929				667				48,216				30,720				3				564				31,287
Compensation and benefits			16,617				2,185				17,853				36,655				18,610				1,280				19,802				39,692
Premium and other taxes			5,992				18				436				6,446				5,564				11				1,328				6,903
Acquisition costs, net (3)			(7,378	)			6,742				—				(636	)			(6,430	)			357				—				(6,073	)
Other underwriting and operating expenses			10,834				980				18,704				30,518				10,390				809				19,403				30,602
Net operating expenses before allocations			26,065				9,925				36,993				72,983				28,134				2,457				40,533				71,124
Corporate expense allocations			11,542				551				(12,093	)			—				12,804				210				(13,014	)			—
Operating expenses after allocations			37,607				10,476				24,900				72,983				40,938				2,667				27,519				71,124
Interest expense			—				—				8,148				8,148				—				—				8,148				8,148
Income (loss) before income taxes		$	190,110			$	15,546			$	1,069			$	206,725			$	193,912			$	20,857			$	(7,770	)		$	206,999
Loss ratio (1)			17.4	%			33.9	%											14.1	%			—	%
Expense ratio (2)			17.4	%			35.7	%											18.8	%			17.0	%
Combined ratio			34.8	%			69.6	%											32.9	%			17.0	%
(1) Loss ratio is calculated by dividing the provision for losses and LAE by net premiums earned.
(2) Expense ratio is calculated by dividing operating expenses after allocations by net premiums earned.
(3) Acquisition costs are net of ceding commissions earned on outward reinsurance and include ceding commissions incurred on reinsurance assumed.

																		Exhibit E
Essent Group Ltd. and Subsidiaries
Supplemental Information
Historical Quarterly Segment Information
(Unaudited)
		Mortgage Insurance
			2026				2025
		March 31				December 31				September 30				June 30				March 31
($ in thousands)
Revenues:
Net premiums earned		$	215,663			$	212,674			$	215,683			$	220,262			$	218,124
Net investment income			42,357				43,627				44,265				43,676				42,790
Realized investment gains (losses), net			(188	)			(218	)			(427	)			(124	)			(101	)
Income (loss) from other invested assets			5,762				2,044				(605	)			3,619				3,209
Other income			1,743				1,149				800				1,614				1,548
Total revenues			265,337				259,276				259,716				269,047				265,570
Losses and expenses:
Provision for losses and LAE			37,620				55,160				44,170				15,323				30,720
Compensation and benefits			16,617				14,727				15,388				15,667				18,610
Premium and other taxes			5,992				6,038				6,010				5,984				5,564
Acquisition costs, net (3)			(7,378	)			(7,234	)			(7,057	)			(6,770	)			(6,430	)
Other underwriting and operating expenses			10,834				11,523				9,735				9,744				10,390
Net operating expenses before allocations			26,065				25,054				24,076				24,625				28,134
Corporate expense allocations			11,542				9,213				7,081				8,979				12,804
Operating expenses after allocations			37,607				34,267				31,157				33,604				40,938
Income before income taxes		$	190,110			$	169,849			$	184,389			$	220,120			$	193,912
Loss ratio (1)			17.4	%			25.9	%			20.5	%			7.0	%			14.1	%
Expense ratio (2)			17.4	%			16.1	%			14.4	%			15.3	%			18.8	%
Combined ratio			34.8	%			42.0	%			34.9	%			22.3	%			32.9	%
(1) Loss ratio is calculated by dividing the provision for losses and LAE by net premiums earned.
(2) Expense ratio is calculated by dividing operating expenses after allocations by net premiums earned.
(3) Acquisition costs are net of ceding commissions earned on outward reinsurance and include ceding commissions incurred on reinsurance assumed.

														Exhibit E, continued
Essent Group Ltd. and Subsidiaries
Supplemental Information
Historical Quarterly Segment Information (Unaudited)
		Reinsurance
			2026				2025
		March 31				December 31				September 30				June 30				March 31
($ in thousands)
Revenues:
Net premiums earned		$	29,310			$	14,696			$	16,304			$	13,875			$	15,734
Net investment income			4,670				4,913				5,302				5,216				4,840
Realized investment gains, net			—				6				—				—				—
Other income			1,971				2,255				1,591				1,909				2,953
Total revenues			35,951				21,870				23,197				21,000				23,527
Losses and expenses:
Provision for losses and LAE			9,929				206				65				36				3
Compensation and benefits			2,185				961				1,180				1,126				1,280
Premium and other taxes			18				17				8				16				11
Acquisition costs, net (3)			6,742				763				487				285				357
Other underwriting and operating expenses			980				996				890				959				809
Net operating expenses before allocations			9,925				2,737				2,565				2,386				2,457
Corporate expense allocations			551				516				502				263				210
Operating expenses after allocations			10,476				3,253				3,067				2,649				2,667
Income before income taxes		$	15,546			$	18,411			$	20,065			$	18,315			$	20,857
Loss ratio (1)			33.9	%			1.4	%			0.4	%			0.3	%			—	%
Expense ratio (2)			35.7	%			22.1	%			18.8	%			19.1	%			17.0	%
Combined ratio			69.6	%			23.5	%			19.2	%			19.4	%			17.0	%
(1) Loss ratio is calculated by dividing the provision for losses and LAE by net premiums earned.
(2) Expense ratio is calculated by dividing operating expenses after allocations by net premiums earned.
(3) Acquisition costs are net of ceding commissions earned on outward reinsurance and include ceding commissions incurred on reinsurance assumed.

						Exhibit E, continued
Essent Group Ltd. and Subsidiaries
Supplemental Information
Historical Quarterly Segment Information
(Unaudited)
		Corporate & Other
			2026				2025
		March 31				December 31				September 30				June 30				March 31
($ in thousands)
Revenues:
Net premiums earned		$	15,120			$	15,359			$	14,345			$	14,672			$	11,990
Net investment income			12,228				10,683				10,228				10,397				10,580
Realized investment gains (losses), net			41				24				2				(5	)			(80	)
Income from other invested assets			4,417				1,898				2,375				847				4,199
Other income			2,978				3,294				1,967				3,185				1,772
Total revenues			34,784				31,258				28,917				29,096				28,461
Losses and expenses:
Provision for losses and LAE			667				707				687				1,696				564
Compensation and benefits			17,853				14,675				12,608				13,926				19,802
Premium and other taxes			436				446				(88	)			495				1,328
Other underwriting and operating expenses			18,704				20,741				20,337				21,333				19,403
Net operating expenses before allocations			36,993				35,862				32,857				35,754				40,533
Corporate expense allocations			(12,093	)			(9,729	)			(7,583	)			(9,242	)			(13,014	)
Operating expenses after allocations			24,900				26,133				25,274				26,512				27,519
Interest expense			8,148				8,149				8,251				8,148				8,148
Income (loss) before income taxes		$	1,069			$	(3,731	)		$	(5,295	)		$	(7,260	)		$	(7,770	)

		Consolidated
			2026				2025
		March 31				December 31				September 30				June 30				March 31
($ in thousands)
Revenues:
Net premiums earned		$	260,093			$	242,729			$	246,332			$	248,809			$	245,848
Net investment income			59,255				59,223				59,795				59,289				58,210
Realized investment gains (losses), net			(147	)			(188	)			(425	)			(129	)			(181	)
Income from other invested assets			10,179				3,942				1,770				4,466				7,408
Other income			6,692				6,698				4,358				6,708				6,273
Total revenues			336,072				312,404				311,830				319,143				317,558
Losses and expenses:
Provision for losses and LAE			48,216				56,073				44,922				17,055				31,287
Compensation and benefits			36,655				30,363				29,176				30,719				39,692
Premium and other taxes			6,446				6,501				5,930				6,495				6,903
Acquisition costs, net (1)			(636	)			(6,471	)			(6,570	)			(6,485	)			(6,073	)
Other underwriting and operating expenses			30,518				33,260				30,962				32,036				30,602
Total other underwriting and operating expenses			72,983				63,653				59,498				62,765				71,124
Interest expense			8,148				8,149				8,251				8,148				8,148
Income before income taxes		$	206,725			$	184,529			$	199,159			$	231,175			$	206,999
(1) Acquisition costs are net of ceding commissions earned on outward reinsurance and include ceding commissions incurred on reinsurance assumed.

										Exhibit F
Essent Group Ltd. and Subsidiaries
Supplemental Information
Mortgage Insurance – Historical Quarterly Data
			2026				2025
		March 31				December 31				September 30				June 30				March 31
($ in thousands)
New insurance written		$	11,076,190			$	11,840,227			$	12,233,252			$	12,544,731			$	9,945,336
New risk written		$	2,893,697			$	3,030,169			$	3,239,497			$	3,357,820			$	2,698,639
Average insurance in force		$	247,838,392			$	248,695,560			$	247,821,046			$	245,747,813			$	244,005,459
Insurance in force (end of period)		$	247,909,417			$	248,356,397			$	248,808,341			$	246,797,619			$	244,692,492
Gross risk in force (end of period) (1)		$	67,916,263			$	68,053,447			$	68,262,577			$	67,683,239			$	67,026,626
Risk in force (end of period)		$	56,271,605			$	56,519,839			$	56,940,929			$	56,811,096			$	56,565,811
Policies in force			801,394				807,230				812,856				812,182				811,342
Weighted average coverage (2)			27.4	%			27.4	%			27.4	%			27.4	%			27.4	%
Annual persistency			84.7	%			85.7	%			86.0	%			85.8	%			85.7	%
Loans in default (count)			20,332				20,210				18,583				17,255				17,759
Percentage of loans in default			2.54	%			2.50	%			2.29	%			2.12	%			2.19	%
Base average premium rate (3)			0.41	%			0.41	%			0.41	%			0.41	%			0.41	%
Single premium cancellations (4)			—	%			—	%			—	%			—	%			—	%
Gross average premium rate			0.41	%			0.41	%			0.41	%			0.41	%			0.41	%
Ceded premiums			(0.06	%)			(0.07	%)			(0.06	%)			(0.05	%)			(0.05	%)
Net average premium rate			0.35	%			0.34	%			0.35	%			0.36	%			0.36	%
(1) Gross risk in force includes risk ceded under third-party reinsurance.
(2) Weighted average coverage is calculated by dividing end of period gross risk in force by end of period insurance in force.
(3) Base average premium rate is calculated by dividing annualized base premiums earned by average insurance in force for the period.
(4) Single premium cancellations is calculated by dividing annualized premiums on the cancellation of non-refundable single premium policies by average insurance in force for the period.

													Exhibit G
Essent Group Ltd. and Subsidiaries
Supplemental Information
Mortgage Insurance – New Insurance Written
NIW by Credit Score
	Three Months Ended
	March 31, 2026						December 31, 2025						March 31, 2025
($ in thousands)
>=760	$	6,118,987		55.2	%		$	6,608,095		55.8	%		$	4,742,099		47.7	%
740-759		1,650,631		14.9				1,905,196		16.1				1,726,055		17.4
720-739		1,252,802		11.4				1,257,994		10.6				1,299,999		13.0
700-719		1,031,226		9.3				1,039,547		8.8				1,164,983		11.7
680-699		567,778		5.1				554,647		4.7				574,657		5.8
<=679		454,766		4.1				474,748		4.0				437,543		4.4
Total	$	11,076,190		100.0	%		$	11,840,227		100.0	%		$	9,945,336		100.0	%
Weighted average credit score		756						757						751
NIW by LTV
	Three Months Ended
	March 31, 2026						December 31, 2025						March 31, 2025
($ in thousands)
85.00% and below	$	1,217,706		11.0	%		$	1,437,750		12.1	%		$	738,619		7.4	%
85.01% to 90.00%		3,199,049		28.9				3,509,133		29.7				2,278,290		22.9
90.01% to 95.00%		5,296,531		47.8				5,663,293		47.8				5,276,018		53.1
95.01% and above		1,362,904		12.3				1,230,051		10.4				1,652,409		16.6
Total	$	11,076,190		100.0	%		$	11,840,227		100.0	%		$	9,945,336		100.0	%
Weighted average LTV		92	%					92	%					93	%
NIW by Product
	Three Months Ended
	March 31, 2026						December 31, 2025						March 31, 2025
Single premium policies				1.6	%					1.6	%					1.4	%
Monthly premium policies				98.4						98.4						98.6
				100.0	%					100.0	%					100.0	%
NIW by Purchase vs. Refinance
	Three Months Ended
	March 31, 2026						December 31, 2025						March 31, 2025
Purchase				72.4	%					72.3	%					94.3	%
Refinance				27.6						27.7						5.7
				100.0	%					100.0	%					100.0	%

														Exhibit H
Essent Group Ltd. and Subsidiaries
Supplemental Information
Mortgage Insurance – Insurance in Force and Risk in Force
Portfolio by Credit Score
IIF by FICO score		March 31, 2026						December 31, 2025						March 31, 2025
($ in thousands)
>=760		$	104,715,580		42.2	%		$	104,062,334		41.9	%		$	100,017,207		40.9	%
740-759			42,906,709		17.3				43,225,016		17.4				42,848,390		17.5
720-739			37,323,783		15.1				37,671,181		15.2				37,970,066		15.5
700-719			32,210,355		13.0				32,473,548		13.1				32,765,594		13.4
680-699			19,194,941		7.7				19,357,527		7.8				19,667,828		8.0
<=679			11,558,049		4.7				11,566,791		4.6				11,423,407		4.7
Total		$	247,909,417		100.0	%		$	248,356,397		100.0	%		$	244,692,492		100.0	%
Weighted average credit score			747						747						746
Gross RIF by FICO score		March 31, 2026						December 31, 2025						March 31, 2025
($ in thousands)
>=760		$	28,401,453		41.9	%		$	28,228,907		41.4	%		$	27,126,072		40.5	%
740-759			11,899,312		17.5				11,997,094		17.6				11,894,259		17.7
720-739			10,356,369		15.2				10,452,268		15.4				10,535,428		15.7
700-719			8,977,150		13.2				9,049,840		13.3				9,113,238		13.6
680-699			5,316,639		7.8				5,357,151		7.9				5,425,408		8.1
<=679			2,965,340		4.4				2,968,187		4.4				2,932,221		4.4
Total		$	67,916,263		100.0	%		$	68,053,447		100.0	%		$	67,026,626		100.0	%
Portfolio by LTV
IIF by LTV		March 31, 2026						December 31, 2025						March 31, 2025
($ in thousands)
85.00% and below		$	14,976,850		6.0	%		$	14,736,797		5.9	%		$	14,375,166		5.9	%
85.01% to 90.00%			57,370,862		23.1				58,288,674		23.5				59,985,533		24.5
90.01% to 95.00%			132,048,705		53.3				131,950,396		53.1				128,443,227		52.5
95.01% and above			43,513,000		17.6				43,380,530		17.5				41,888,566		17.1
Total		$	247,909,417		100.0	%		$	248,356,397		100.0	%		$	244,692,492		100.0	%
Weighted average LTV			93	%					93	%					93	%
Gross RIF by LTV		March 31, 2026						December 31, 2025						March 31, 2025
($ in thousands)
85.00% and below		$	1,752,508		2.6	%		$	1,727,701		2.5	%		$	1,701,075		2.5	%
85.01% to 90.00%			14,061,350		20.7				14,312,312		21.0				14,799,254		22.1
90.01% to 95.00%			38,936,750		57.3				38,906,277		57.2				37,888,529		56.5
95.01% and above			13,165,655		19.4				13,107,157		19.3				12,637,768		18.9
Total		$	67,916,263		100.0	%		$	68,053,447		100.0	%		$	67,026,626		100.0	%
Portfolio by Loan Amortization Period
IIF by Loan Amortization Period		March 31, 2026						December 31, 2025						March 31, 2025
($ in thousands)
FRM 30 years and higher		$	240,268,121		96.9	%		$	241,353,234		97.2	%		$	239,398,817		97.8	%
FRM 20-25 years			1,631,244		0.7				1,449,192		0.6				1,042,318		0.4
FRM 15 years			2,214,086		0.9				2,009,940		0.8				1,285,597		0.5
ARM 5 years and higher			3,795,966		1.5				3,544,031		1.4				2,965,760		1.3
Total		$	247,909,417		100.0	%		$	248,356,397		100.0	%		$	244,692,492		100.0	%

																				Exhibit I
Essent Group Ltd. and Subsidiaries
Supplemental Information
Mortgage Insurance – Vintage Data
March 31, 2026
								Insurance in Force
Year	Original Insurance Written ($ in thousands)		Remaining Insurance in Force ($ in thousands)		% Remaining of Original Insurance		Number of Policies in Force	Weighted Average Coupon		% Purchase		>90% LTV		>95% LTV		FICO < 700		FICO >= 760		Incurred Loss Ratio (Inception to Date) (1)		Number of Loans in Default	Percentage of Loans in Default
2010 – 2016	$	121,811,826	$	2,488,061	2.0	%	13,763	4.19	%	71.8	%	53.4	%	4.7	%	13.2	%	45.2	%	2.2	%	600	4.36	%
2017		43,858,322		2,536,413	5.8		16,320	4.34		89.9		80.8		27.8		22.1		35.7		2.9		784	4.80
2018		47,508,525		3,531,305	7.4		21,052	4.84		95.2		82.6		31.3		23.1		30.5		3.8		1,050	4.99
2019		63,569,183		8,047,902	12.7		41,367	4.27		90.8		77.7		28.2		19.8		33.7		3.5		1,516	3.66
2020		107,944,065		25,840,280	23.9		108,568	3.22		78.4		72.6		17.2		11.2		44.4		2.7		2,306	2.12
2021		84,218,250		39,109,055	46.4		137,011	3.11		93.0		73.9		19.1		13.7		39.9		6.5		3,649	2.66
2022		63,061,262		43,970,638	69.7		130,508	5.09		98.5		68.2		12.1		12.5		39.4		20.3		3,882	2.97
2023		47,666,852		33,537,692	70.4		98,493	6.57		98.9		73.9		19.8		11.2		37.9		25.0		3,430	3.48
2024		45,561,332		36,126,344	79.3		99,820	6.67		95.1		73.9		21.1		12.7		41.5		23.9		2,367	2.37
2025		46,563,546		41,706,357	89.6		107,884	6.55		87.0		65.4		15.5		10.4		49.7		15.7		740	0.69
2026 (through March 31)		11,076,190		11,015,370	99.5		26,608	6.03		72.3		60.1		12.3		9.3		55.1		3.5		8	0.03
Total	$	682,839,353	$	247,909,417	36.3		801,394	5.25		91.3		70.8		17.6		12.4		42.2		6.6		20,332	2.54
(1) Incurred loss ratio is calculated by dividing the sum of case reserves and cumulative amount paid for claims by cumulative net premiums earned.

	Essent Group Ltd. and Subsidiaries	Exhibit J
	Supplemental Information
	Mortgage Insurance – Outward Reinsurance Vintage Data
	March 31, 2026

($ in thousands)
Insurance Linked Notes (1)
Deal Name	Vintage	Remaining Insurance in Force		Remaining Risk in Force			Original Reinsurance in Force			Remaining Reinsurance in Force			Losses Ceded to Date			Original First Layer Retention		Remaining First Layer Retention			Earned Premiums Ceded Year-to-Date			Reduction in PMIERs Minimum Required Assets (3)
Radnor Re 2021-1	Aug. 2020 – Mar. 2021	$	17,192,389	$	4,799,485		$	557,911		$	74,611		$	—		$	278,956	$	275,746		$	784		$	38,306
Radnor Re 2021-2	Apr. 2021 – Sep. 2021		23,399,809		6,664,825			439,407			178,351			—			279,415		269,613			2,390			162,633
Radnor Re 2022-1	Oct. 2021 – Jul. 2022		23,407,727		6,529,964			237,868			121,243			—			303,761		288,498			2,565			121,243
Radnor Re 2023-1	Aug. 2022 – Jun. 2023		23,806,743		6,559,432			281,462			196,750			—			281,463		268,187			2,682			196,750
Radnor Re 2024-1	Jul. 2023 – Jul. 2024		23,066,718		6,394,625			363,366			220,773			—			256,495		253,795			2,386			163,372
Total		$	110,873,386	$	30,948,331		$	1,880,014		$	791,728		$	—		$	1,400,090	$	1,355,839		$	10,807		$	682,304

Excess of Loss Reinsurance (2)
Deal Name	Vintage	Remaining Insurance in Force		Remaining Risk in Force			Original Reinsurance in Force			Remaining Reinsurance in Force			Losses Ceded to Date			Original First Layer Retention		Remaining First Layer Retention			Earned Premiums Ceded Year-to-Date			Reduction in PMIERs Minimum Required Assets (3)
(4) XOL 2019-1	Jan. 2018 – Dec. 2018	$	—	$	—		$	—		$	—		$	—		$	—	$	—		$	374		$	—
XOL 2020-1	Jan. 2019 – Aug. 2019		4,621,398		1,226,788			55,102			29,152			—			215,605		210,230			246			—
XOL 2022-1	Oct. 2021 – Dec. 2022		53,242,769		14,741,381			141,992			133,426			—			507,114		465,688			1,486			128,755
XOL 2023-1	Jan. 2023 – Dec. 2023		30,307,586		8,428,861			36,627			34,676			—			366,270		355,763			406			33,339
XOL 2024-1	Jan. 2024 – Dec. 2024		33,498,856		9,232,623			58,005			58,005			—			331,456		329,277			644			55,894
XOL 2025-1	Jan. 2025 – Dec. 2025		41,645,386		11,037,984			80,821			80,821			—			343,234		343,234			717			77,847
Total		$	163,315,995	$	44,667,637		$	372,547		$	336,080		$	—		$	1,763,679	$	1,704,192		$	3,873		$	295,835

Quota Share Reinsurance (2)
Year	Ceding Percentage		Remaining Insurance in Force		Remaining Risk in Force			Remaining Ceded Insurance in Force			Remaining Ceded Risk in Force			Losses Ceded Year-to-Date			Ceding Commission Year-to-Date			Earned Premiums Ceded Year-to-Date			Reduction in PMIERs Minimum Required Assets (3)
Sep. 2019 – Dec. 2020	(5)		$	29,235,185	$	8,112,049		$	6,080,065		$	1,662,242		$	11		$	1,792		$	2,596		$	103,959
Jan. 2022 – Dec. 2022	20%			43,925,225		12,103,933			8,785,045			2,420,787			2,100			1,588			4,880			180,735
Jan. 2023 – Dec. 2023	17.5%			30,220,125		8,407,273			5,288,522			1,471,273			2,603			1,110			4,934			120,620
Jan. 2024 – Dec. 2024	15%			35,919,887		9,883,294			5,387,983			1,482,494			1,469			1,155			3,953			122,999
Jan. 2025 – Dec. 2025	25%			41,672,274		11,045,436			10,418,068			2,761,359			1,837			1,833			5,227			186,064
Jan. 2026 – Dec. 2026	25%			11,002,696		2,874,779			2,750,674			718,695			28			159			293			43,021
Total			$	191,975,392	$	52,426,764		$	38,710,357		$	10,516,850		$	8,048		$	7,637		$	21,883		$	757,398

(1) Reinsurance provided by unaffiliated special purpose insurers through the issuance of mortgage insurance-linked notes (“ILNs”).

(2) Reinsurance provided by panels of reinsurers.

(3) Represents the reduction in Essent Guaranty, Inc.’s Minimum Required Assets based on our interpretation of the PMIERs.

(4) XOL 2019-1 terminated as of February 2026.

(5) Under QSR-2019, Essent Guaranty cedes 36% of premiums on singles policies and 18% on all other policies.

						Exhibit K
Essent Group Ltd. and Subsidiaries
Supplemental Information
Mortgage Insurance – Geographic Data
IIF by State
	March 31, 2026			December 31, 2025			March 31, 2025
CA	12.1	%		12.1	%		12.4	%
FL	12.0			12.0			11.9
TX	11.5			11.4			11.2
AZ	4.1			4.0			3.9
CO	4.0			4.0			4.0
GA	3.9			3.9			3.8
WA	3.4			3.4			3.4
NC	3.2			3.2			3.1
NY	2.6			2.6			2.6
MI	2.6			2.6			2.5
All Others	40.6			40.8			41.2
Total	100.0	%		100.0	%		100.0	%
Gross RIF by State
	March 31, 2026			December 31, 2025			March 31, 2025
FL	12.3	%		12.3	%		12.1	%
CA	12.1			12.1			12.4
TX	11.7			11.6			11.5
AZ	4.2			4.1			3.9
GA	3.9			3.9			3.8
CO	3.9			3.9			4.0
WA	3.4			3.4			3.4
NC	3.2			3.2			3.1
MI	2.6			2.6			2.6
UT	2.6			2.6			2.5
All Others	40.1			40.3			40.7
Total	100.0	%		100.0	%		100.0	%

														Exhibit L
Essent Group Ltd. and Subsidiaries
Supplemental Information
Mortgage Insurance
Rollforward of Defaults and Reserve for Losses and LAE
Rollforward of Insured Loans in Default
		Three Months Ended
			2026				2025
		March 31				December 31				September 30				June 30				March 31
Beginning default inventory			20,210				18,583				17,255				17,759				18,439
Plus: new defaults (A)			11,100				11,245				10,357				8,810				9,664
Less: cures			(10,708	)			(9,357	)			(8,713	)			(9,078	)			(10,173	)
Less: claims paid			(239	)			(235	)			(296	)			(215	)			(153	)
Less: rescissions and denials, net			(31	)			(26	)			(20	)			(21	)			(18	)
Ending default inventory			20,332				20,210				18,583				17,255				17,759
(A) New defaults remaining as of March 31, 2026			7,785				4,323				2,750				1,640				1,031
Cure rate (1)			30	%			62	%			73	%			81	%			89	%
Total amount paid for claims (in thousands)		$	13,671			$	13,171			$	16,456			$	9,007			$	6,330
Average amount paid per claim (in thousands)		$	57			$	56			$	56			$	42			$	41
Severity			84	%			80	%			78	%			67	%			70	%
Rollforward of Reserve for Losses and LAE
		Three Months Ended
			2026				2025
($ in thousands)		March 31				December 31				September 30				June 30				March 31
Reserve for losses and LAE at beginning of period		$	429,610			$	379,548			$	345,952			$	338,128			$	310,156
Less: Reinsurance recoverables			56,120				47,957				41,966				40,351				36,655
Net reserve for losses and LAE at beginning of period			373,490				331,591				303,986				297,777				273,501
Add provision for losses and LAE occurring in:
Current period			62,792				67,865				62,349				45,119				48,928
Prior years			(25,172	)			(12,705	)			(18,179	)			(29,796	)			(18,208	)
Incurred losses and LAE during the period			37,620				55,160				44,170				15,323				30,720
Deduct payments for losses and LAE occurring in:
Current period			88				2,649				552				315				51
Prior years			13,712				10,612				16,013				8,799				6,393
Loss and LAE payments during the period			13,800				13,261				16,565				9,114				6,444
Net reserve for losses and LAE at end of period			397,310				373,490				331,591				303,986				297,777
Plus: Reinsurance recoverables			61,591				56,120				47,957				41,966				40,351
Reserve for losses and LAE at end of period		$	458,901			$	429,610			$	379,548			$	345,952			$	338,128
(1) The cure rate is calculated by dividing new defaults remaining as of the reporting date by the original number of new defaults reported in the quarterly period and subtracting that percentage from 100%.

										Exhibit M
Essent Group Ltd. and Subsidiaries
Supplemental Information
Mortgage Insurance
Detail of Reserves by Default Delinquency
		March 31, 2026
		Number of Policies in Default		Percentage of Policies in Default		Amount of Reserves		Percentage of Reserves		Defaulted RIF		Reserves as a Percentage of Defaulted RIF
($ in thousands)
Missed Payments:
Two payments		6,564		32	%	$	38,398	9	%	$	533,428	7	%
Three payments		2,797		14			29,040	7			231,329	13
Four to eleven payments		7,802		38			181,134	43			675,553	27
Twelve or more payments		2,761		14			148,384	35			231,640	64
Pending claims		408		2			27,091	6			30,357	89
Total case reserves		20,332		100	%		424,047	100	%	$	1,702,307	25	%
IBNR							31,804
LAE							3,050
Total reserves for losses and LAE						$	458,901
Average reserve per default:
Case						$	20.9
Total						$	22.6
Default Rate		2.54	%
3+ Month Default Rate		1.72	%
		December 31, 2025
		Number of Policies in Default		Percentage of Policies in Default		Amount of Reserves		Percentage of Reserves		Defaulted RIF		Reserves as a Percentage of Defaulted RIF
($ in thousands)
Missed Payments:
Two payments		6,892		34	%	$	40,876	10	%	$	545,198	7	%
Three payments		3,002		15			32,458	8			246,194	13
Four to eleven payments		7,261		36			163,087	41			615,449	26
Twelve or more payments		2,742		13			139,036	35			224,248	62
Pending claims		313		2			21,360	6			23,797	90
Total case reserves		20,210		100	%		396,817	100	%	$	1,654,886	24	%
IBNR							29,761
LAE							3,032
Total reserves for losses and LAE						$	429,610
Average reserve per default:
Case						$	19.6
Total						$	21.3
Default Rate		2.50	%
3+ Month Default Rate		1.65	%
		March 31, 2025
		Number of Policies in Default		Percentage of Policies in Default		Amount of Reserves		Percentage of Reserves		Defaulted RIF		Reserves as a Percentage of Defaulted RIF
($ in thousands)
Missed Payments:
Two payments		5,430		31	%	$	29,226	9	%	$	426,195	7	%
Three payments		2,445		14			23,046	7			194,642	12
Four to eleven payments		7,472		42			139,810	45			620,538	23
Twelve or more payments		2,198		12			105,783	34			172,129	61
Pending claims		214		1			14,195	5			15,789	90
Total case reserves		17,759		100	%		312,060	100	%	$	1,429,293	22	%
IBNR							23,404
LAE							2,664
Total reserves for losses and LAE						$	338,128
Average reserve per default:
Case						$	17.6
Total						$	19.0
Default Rate		2.19	%
3+ Month Default Rate		1.52	%

														Exhibit N
Essent Group Ltd. and Subsidiaries
Supplemental Information
U.S. Mortgage Insurance Company Capital
			2026				2025
		March 31				December 31				September 30				June 30				March 31
($ in thousands)
Essent Guaranty, Inc:
Statutory capital		$	3,682,476			$	3,572,887			$	3,732,465			$	3,714,146			$	3,642,374
Net risk in force (1)		$	31,785,517			$	32,486,788			$	33,367,706			$	33,986,508			$	34,968,089
Risk-to-capital ratio (2)			8.6:1				9.1:1				8.9:1				9.2:1				9.6:1
Essent Guaranty, Inc. PMIERs Data (3):
Available Assets		$	3,635,459			$	3,520,454			$	3,666,883			$	3,654,460			$	3,628,675
Minimum Required Assets			2,084,042				2,087,473				2,065,890				2,075,409				2,107,620
PMIERs excess Available Assets		$	1,551,417			$	1,432,981			$	1,600,993			$	1,579,051			$	1,521,055
PMIERs sufficiency ratio (4)			174	%			169	%			177	%			176	%			172	%
(1) Net risk in force represents total risk in force, net of reinsurance ceded and net of exposures on policies for which loss reserves have been established.
(2) The risk-to-capital ratio is calculated as the ratio of net risk in force to statutory capital.
(3) Data is based on our interpretation of the PMIERs as of the dates indicated.
(4) PMIERs sufficiency ratio is calculated by dividing Available Assets by Minimum Required Assets.

														Exhibit O
Essent Group Ltd. and Subsidiaries
Supplemental Information
Reinsurance
			2026				2025
($ in thousands)		March 31				December 31				September 30				June 30				March 31
Net Premiums Written:
Mortgage		$	13,236			$	15,117			$	18,338			$	13,181			$	16,921
Non-mortgage			156,365				633				359				229				229
Total		$	169,601			$	15,750			$	18,697			$	13,410			$	17,150
Net Premiums Earned:
Mortgage		$	12,264			$	14,063			$	15,945			$	13,646			$	15,505
Non-mortgage			17,046				633				359				229				229
Total		$	29,310			$	14,696			$	16,304			$	13,875			$	15,734
Reserve for losses and LAE		$	10,076			$	359			$	153			$	88			$	52
Mortgage Reinsurance Statistics:
Reinsured risk in force		$	2,084,380			$	2,166,605			$	2,184,981			$	2,290,008			$	2,189,477
Weighted average credit score			751				751				751				751				751
Weighted average LTV			83	%			83	%			83	%			83	%			82	%
Essent Reinsurance Ltd. Capital:
Stockholder’s equity (GAAP basis)		$	1,660,416			$	1,695,390			$	1,722,135			$	1,751,720			$	1,780,924

									Exhibit P
Essent Group Ltd. and Subsidiaries
Supplemental Information
Cash & Investments
Cash & Investments by Asset Class
Asset Class		March 31, 2026							December 31, 2025
($ in thousands)		Fair Value				Percent			Fair Value			Percent
U.S. Treasury securities		$	332,065			5.1	%		$	369,712		5.6	%
U.S. agency mortgage-backed securities			1,143,120			17.4				1,174,895		17.8
Municipal debt securities			608,683			9.3				610,411		9.2
Non-U.S. government securities			54,720			0.8				56,024		0.8
Corporate debt securities			1,936,708			29.4				1,980,080		30.0
Residential and commercial mortgage securities			462,048			7.0				464,105		7.0
Asset-backed securities			887,866			13.5				800,366		12.1
Money market funds			623,034			9.5				648,492		9.8
Total investments available for sale		$	6,048,244			92.0	%		$	6,104,085		92.3	%
Other invested assets			394,290			6.0				382,513		5.8
Cash			128,262			2.0				123,049		1.9
Total cash and investments		$	6,570,796			100.0	%		$	6,609,647		100.0	%
Investments Available for Sale by Credit Rating
Rating (1)		March 31, 2026							December 31, 2025
($ in thousands)		Fair Value				Percent			Fair Value			Percent
Aaa		$	871,259			16.1	%		$	846,230		15.5	%
Aa1			1,731,957			31.9				1,799,508		32.9
Aa2			347,838			6.4				300,026		5.5
Aa3			318,197			5.9				319,848		5.9
A1			525,198			9.7				545,918		10.0
A2			517,108			9.5				511,146		9.4
A3			481,244			8.9				494,434		9.1
Baa1			242,069			4.5				244,424		4.5
Baa2			188,885			3.5				208,247		3.8
Baa3			136,746			2.5				122,596		2.2
Below Baa3			64,709			1.1				63,216		1.2
Total (2)		$	5,425,210			100.0	%		$	5,455,593		100.0	%
(1) Based on ratings issued by Moody’s, if available. S&P or Fitch rating utilized if Moody’s not available.
(2) Excludes $623,034 and $648,492 of money market funds at March 31, 2026 and December 31, 2025, respectively.
Investments Available for Sale by Duration and Book Yield
Effective Duration		March 31, 2026							December 31, 2025
($ in thousands)		Fair Value				Percent			Fair Value			Percent
< 1 Year		$	1,582,563			26.2	%		$	1,549,327		25.4	%
1 to < 2 Years			532,437			8.8				527,914		8.6
2 to < 3 Years			483,762			8.0				532,211		8.7
3 to < 4 Years			666,215			11.0				571,255		9.4
4 to < 5 Years			437,751			7.2				536,135		8.8
5 or more Years			2,345,516			38.8				2,387,243		39.1
Total investments available for sale		$	6,048,244			100.0	%		$	6,104,085		100.0	%
Pre-tax investment yield (3)		Three Months Ended March 31, 2026
Yield on cash and investments available for sale			3.80	%
Return on other invested assets			10.56	%
Aggregate yield on total cash and investments			4.18	%
(3) Yield on cash and investments available for sale is calculated as the annualized gross investment income earned divided by the average amortized cost of cash and investments available for sale. Return on other invested assets is calculated as annualized income (loss) from other invested assets divided by the average balance of other invested assets. The aggregate yield is calculated as the sum of the numerators in the calculations described above divided by the sum of denominators in the calculations described above.